Should you buy these 3 beaten-up growth shares?

Many investors would be pretty pleased with the fact that most of the top 20 ASX shares, including the big four banks and major miners, have enjoyed a great run over the past 12 months.

However, I feel that there isn’t a lot of value left in many of the big name shares right now and that investors should start to look at other alternatives.

Fortunately, there are a number of shares that are currently offering pretty enticing risk-reward propositions, including:

Mantra Group Ltd (ASX: MTR)

The Mantra share price is trading at a 35% discount to its 52-week highs, largely on the back of fears of an oversupply of hotel rooms and the potential impact from Airbnb. The shares have been supported more recently on rumours of a takeover, although this has not progressed any further. Nonetheless, I wouldn’t be surprised if Mantra is currently being looked at by possible suitors considering the growth of the tourism sector in Australia. Even without a takeover offer, I think Mantra currently offers an attractive value proposition considering the shares trade on around 16x earnings and a forecast grossed up dividend yield of around 6.5%.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price has fallen around 36% from its 52-week highs thanks to an ongoing U.S. investigation into allegations of price-fixing. Some investors have also been concerned about potential changes to the American health system under the new Trump administration. These are two important issues the generic drug company has to contend with, but I believe these short-term risks are now more than adequately reflected in the current valuation. At $1.35 per share, Mayne Pharma is trading on a historically low earnings multiple of less than 15x.

Catapult Group International Ltd (ASX: CAT)

The Catapult share price has fallen by more than 50% over the past nine months, despite the sport analytics company continuing to sign-up new sporting teams at an impressive rate. Unfortunately, the company’s burgeoning top line growth hasn’t been translated into any meaningful profitability yet and this has left some investors feeling frustrated. Nonetheless, Catapult is continuing to build scale and is developing a very fast-growing recurring revenue base that will be a crucial growth driver moving forward. As a result, I wouldn’t write the company off just yet, although the shares are definitely only suitable for risk-tolerant investors.

Are you worried about where the share market might be heading?

For Investors Who Are Anxious About 2017

In 2017, the share market could have its most volatile year ever. That's why one Foolish expert is revealing 5 of his favorite dividend payers now. These "strong and steady" shares promise a healthy stream of income plus capital gains...

But you must act now. This newly updated report is available for a limited time only, and your copy is 100% free. So don't miss out!

Simply click here to receive your free copy of "Our Top 5 ASX Dividend Shares to Earn You Money in 2017" right now.

Motley Fool contributor Christopher Georges owns shares of MANTRA GRP FPO and Mayne Pharma Group Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.